These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29199066)

  • 1. Abuse liability assessment for biologic drugs - All molecules are not created equal.
    de Zafra CLZ; Markgraf CG; Compton DR; Hudzik TJ
    Regul Toxicol Pharmacol; 2018 Feb; 92():165-172. PubMed ID: 29199066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical assessment of abuse liability of biologics: In defense of current regulatory control policies.
    Gauvin DV; Zimmermann ZJ; Baird TJ
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):43-54. PubMed ID: 26107292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In further defense of nonclinical abuse liability testing of biologics.
    Gauvin DV; Zimmermann ZJ; Baird TJ
    Regul Toxicol Pharmacol; 2019 Feb; 101():103-120. PubMed ID: 30465804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
    Swedberg MD
    J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
    de Zafra CLZ; Sasseville VG; Matsumoto S; Freichel C; Milton M; MacLachlan TK; Farman C; Raymond I; Gupta S; Newton R; Atzpodien EA; Thackaberry EA
    Regul Toxicol Pharmacol; 2017 Jun; 86():221-230. PubMed ID: 28322894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical Tools to Assess Risk of Drug Hypersensitivity Reactions.
    Whritenour J; Casinghino S; Collinge M; Zhu X
    Annu Rev Pharmacol Toxicol; 2016; 56():561-76. PubMed ID: 26514195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.
    Frazier KS; Engelhardt JA; Fant P; Guionaud S; Henry SP; Leach MW; Louden C; Scicchitano MS; Weaver JL; Zabka TS;
    Toxicol Pathol; 2015 Oct; 43(7):915-34. PubMed ID: 25722122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating the assessment of abuse liability into the drug discovery and development process.
    Mansbach RS; Feltner DE; Gold LH; Schnoll SH
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S73-85. PubMed ID: 12759198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
    Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of the abuse liability of drugs.
    Johanson CE
    Drug Saf; 1990; 5 Suppl 1():46-57. PubMed ID: 2182063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
    MacLachlan TK; Kronenberg S; Marshall N; Andrews L; Berens SJ; Brouta F; Fogal B; Freebern W; Herzyk D; Kamperschroer C; Kiessling A; Schneidkraut M; Maier C
    Regul Toxicol Pharmacol; 2021 Feb; 119():104825. PubMed ID: 33220389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.
    Vargas HM; Bass AS; Breidenbach A; Feldman HS; Gintant GA; Harmer AR; Heath B; Hoffmann P; Lagrutta A; Leishman D; McMahon N; Mittelstadt S; Polonchuk L; Pugsley MK; Salata JJ; Valentin JP
    J Pharmacol Toxicol Methods; 2008; 58(2):72-6. PubMed ID: 18508287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.
    Everds NE; Tarrant JM
    Toxicol Pathol; 2013 Feb; 41(2):280-302. PubMed ID: 23471185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Pharmacology Evaluation of Biopharmaceuticals.
    Amouzadeh HR; Engwall MJ; Vargas HM
    Handb Exp Pharmacol; 2015; 229():385-404. PubMed ID: 26091648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proactive nonclinical drug abuse and dependence liability assessment strategy: a sponsor perspective.
    Swedberg MD
    Behav Pharmacol; 2013 Sep; 24(5-6):396-402. PubMed ID: 23907375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New challenges and opportunities in nonclinical safety testing of biologics.
    Baumann A; Flagella K; Forster R; de Haan L; Kronenberg S; Locher M; Richter WF; Theil FP; Todd M
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):226-33. PubMed ID: 24755365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity/hypersensitivity of biologics.
    Leach MW; Rottman JB; Hock MB; Finco D; Rojko JL; Beyer JC
    Toxicol Pathol; 2014 Jan; 42(1):293-300. PubMed ID: 24240973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.